Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery. Gemcitabine is an important chemotherapeutic agent for patients with PDAC; however, the efficacy of gem...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Danqi, Yan, Jingrui, Zhang, Zhaoyu, Liu, Yang, Ma, Xiaoqing, Ding, Jinsheng, Yang, Shengyu, Zhao, Ran, Chang, Antao, Gao, Chuntao, Liu, Jing, Zhao, Tiansuo, Wang, Xiuchao, Huang, Chongbiao, Gao, Song, Ma, Ying, Tang, Bo, Feng, Yukuan, Wang, Hongwei, Hao, Jihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476466/
https://www.ncbi.nlm.nih.gov/pubmed/37381714
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476466/
https://www.ncbi.nlm.nih.gov/pubmed/37381714
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0039

Ejemplares similares